Nichol Ochsner

Professional Summary

Professional Overview
Nichol Ochsner is an accomplished investor relations and corporate communications professional with extensive experience in the biopharmaceutical industry. As the Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics, she leverages her deep expertise to effectively engage with the investment community and drive strategic communications initiatives.

Experience Summary

Current Role
Nichol currently serves as the Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics, a leading biopharmaceutical company. In this role, she is responsible for developing and executing comprehensive investor relations and corporate communications strategies to enhance the company's visibility, transparency, and shareholder value. She plays a pivotal role in maintaining strong relationships with the investment community, communicating Zevra's strategic vision, and ensuring accurate and timely dissemination of information.

Career Progression
Prior to her current position, Nichol held senior-level roles in investor relations and corporate communications at various biopharmaceutical companies. She served as the Executive Vice President of Investor Relations and Corporate Communications at Statera BioPharma, Inc., the Vice President of Investor Relations at TherapeuticsMD, and the Executive Director of Investor Relations and Corporate Communications at Aralez Pharmaceuticals Inc. and Endo International plc (formerly Auxilium). Throughout her career, Nichol has demonstrated a track record of driving impactful investor relations and communications initiatives, contributing to the growth and success of the organizations she has been a part of.

Academic Background
Nichol holds a bachelor's degree from a reputable university, where she honed her skills in finance and communications. Her academic background provides a strong foundation for her work in the biopharmaceutical industry.

Areas of Expertise

• Investor relations strategy and execution

• Corporate communications and messaging

• Stakeholder engagement and relationship management

• Financial and operational performance reporting

• Biotechnology and pharmaceutical industry knowledge

• Strategic planning and implementation

• Cross-functional collaboration and leadership

Professional Impact
Nichol has consistently made significant contributions to the companies she has worked for. She has played a pivotal role in enhancing investor confidence, improving corporate visibility, and securing strategic partnerships. Her ability to effectively communicate complex information and build strong relationships with the investment community has been instrumental in driving shareholder value and support for her employers' initiatives.

Conclusion
With her extensive experience, industry expertise, and proven track record of success, Nichol Ochsner is a valuable asset to the biopharmaceutical industry. As the Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics, she is poised to continue driving impactful communications and investor engagement strategies that contribute to the company's long-term growth and success.